Our data demonstrate that blocking PERK activation inhibits BRAFi-resistant melanoma growth and suggest that PERK is a promising diagnostic marker and therapeutic target for BRAFi-resistant melanoma with impaired PTEN. The gene discussed is EIF2AK3; the disease is melanoma.